retatrutide clinical trial dosing frequency Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a How to Dose Retatrutide: UK

Lipid Profile Improvements Treatment with retatrutide resulted in favorable changes to lipid profiles: Reduced triglycerides, with bias toward reduction in short-chain and saturated species Decreased LDL and VLDL cholesterol Improved markers associated with enhanced insulin sensitivity and reduced systemic inflammation[3] These changes in lipid metabolism may contribute to retatrutide's cardiometabolic benefits and warrant further investigation for potential cardiovascular outcome benefits

The ADA now recommends GLP1 RAs with proven benefit to slow CKD progression and reduce CV risk in people with type 2 diabetes

PlexusDx providers evaluate your complete health history before prescribing

We pair proven science with compassionate support to help you